INTRODUCTION
Rabies is a rapidly progressive encephalomyelitis with a very high case fatality rate. Approximately 55 000 people worldwide, nearly half of whom are children, die annually of rabies. Rabies is caused by RNA viruses in the family Rhabdoviridae, genus lyssavirus. In the Americas, only type 1 lyssavirus (rabies virus) circulates and is common in wild animals, particularly bats, coyotes, foxes, raccoons, and skunks, in the United States. Virus is transmitted in the saliva of rabid mammals after a bite or through contamination of an open wound or mucous membrane. The incubation period (1-3 months) is long enough to render immunization a highly effective strategy for postexposure prophylaxis (PEP). Approximately 20 000 to 30 000 persons receive PEP in the United States each year, and 1 to 3 cases of human rabies occurs annually. Between 2000 and 2007, 20 of 25 cases of human rabies reported in the United States were acquired within the United States. Among the 20 indigenously acquired cases, 17 were associated with bat rabies virus variants.
In the United States, animal rabies is common. Education of children to avoid contact with stray or wild animals is of primary importance. PEP is indicated once an exposure has occurred. PEP has never failed in the United States since the introduction of modern cell-derived vaccines in the 1970s. Keys to effective PEP have included prompt washing of the wound with copious amounts of soap and water, infiltration of human rabies immunoglobulin into and around the wound, and a 5-dose schedule of intramuscular vaccine administered over 28 days.
BACKGROUND AND RATIONALE
In 2007, when human rabies vaccine was in limited supply, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention formed a rabies work group to review rabies vac- 
EVIDENCE TO SUPPORT THE RECOMMENDATION
A detailed review of the evidence in support of a reduced, 4-dose schedule for human PEP has been published. 2 • The induction of rabies-neutralizing antibody is a surrogate for an adequate immune response to vaccination and was achieved in all subjects (ϳ1000) by day 14, when the fourth dose of cell-derived rabies vaccine was given.
• From observational studies that included persons likely exposed to confirmed rabid animals and with imperfect adherence to the 5-dose vaccine schedule, the Rabies Working Group estimated that more than 300 persons in the United States received only 3 or 4 doses annually, and there were no resulting cases of human rabies. Although human PEP failures do occur rarely worldwide, no cases have been attributed to the lack of receipt of the fifth rabies vaccine dose on day 28.
• In animal models ranging from rodents to nonhuman primates, timely PEP was important, but the absolute number of vaccine doses did not contribute to significant differences in survival rates.
• Adverse reactions to the modern cell-derived rabies vaccines are uncommon in children and, theoretically, will be the same or less common with 1 less vaccine dose.
• Preliminary economic assessments indicate that there would be a $16 million cost savings to the United States health care system by using the reduced-dose schedule. 
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